Jenscare Scientific Co. Ltd. Class H (HK:9877)
:9877
Want to see HK:9877 full AI Analyst Report?
9877 Stock Chart & Stats
HK$9.48
HK$0.16(3.97%)
At close: 4:00 PM EST
HK$9.48
HK$0.16(3.97%)
Day’s Range― - ―
52-Week RangeHK$5.90 - HK$11.98
Previous CloseN/A
Volume216.80K
Average Volume (3M)805.10K
Market Cap
HK$5.37B
Enterprise ValueHK$2.99B
Total Cash (Recent Filing)HK$527.63M
Total Debt (Recent Filing)HK$47.38M
Price to Earnings (P/E)―
Beta0.70
Next Earnings
Sep 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.44
Shares Outstanding310,306,200
10 Day Avg. Volume637,060
30 Day Avg. Volume805,099
Financial Highlights & Ratios
PEG Ratio-0.26
Price to Book (P/B)4.22
Price to Sales (P/S)37.79
P/FCF Ratio-41.65
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.09
Revenue Forecast (FY)HK$261.02M
Bulls Say, Bears Say
Bulls Say
Revenue Ramp / CommercializationA sharp revenue ramp to about $88M in 2025 signals meaningful commercial traction for Jenscare’s transcatheter devices. Durable revenue growth off a low base indicates initial market adoption and supports scaling operating leverage as the company expands sales and clinical penetration over months.
High Gross MarginsSustained gross margins near 75% imply attractive unit economics for the company’s minimally invasive devices. High product-level profitability provides a structural advantage: as revenue scales, gross-profit conversion can fund R&D and sales, improving prospects for eventual operating profitability.
Low Financial LeverageVery low debt relative to equity reduces solvency risk and preserves strategic flexibility. Light leverage gives management more runway to invest in commercialization and R&D without immediate fixed-charge pressure, important while revenue scales and cash generation normalizes.
Bears Say
Large Net LossesA cumulative net loss of roughly $264M in 2025 reflects operating expenses far outpacing current revenue. Persistent large losses undermine equity resilience and require a clear path to margin expansion and expense control before the business can sustainably convert its strong unit economics into positive net earnings.
Negative Operating And Free Cash FlowContinued negative operating and free cash flow indicate the company is still consuming capital to run and invest in the business. Even with improvement, ongoing cash burn implies near-term funding needs and potential dilution risk unless cash generation accelerates or external financing is secured.
Negative Return On EquityA ROE near -33% shows shareholder capital is not generating returns and highlights earnings quality issues. Over time, sustained negative ROE can pressure investor confidence, force capital raises, and dilute existing holders if management cannot translate revenue growth and margins into positive returns.
Jenscare Scientific Co. Ltd. Class H News
9877 FAQ
What was Jenscare Scientific Co. Ltd. Class H’s price range in the past 12 months?
Jenscare Scientific Co. Ltd. Class H lowest stock price was HK$5.90 and its highest was HK$11.98 in the past 12 months.
What is Jenscare Scientific Co. Ltd. Class H’s market cap?
Jenscare Scientific Co. Ltd. Class H’s market cap is HK$5.37B.
When is Jenscare Scientific Co. Ltd. Class H’s upcoming earnings report date?
Jenscare Scientific Co. Ltd. Class H’s upcoming earnings report date is Sep 02, 2026 which is in 116 days.
How were Jenscare Scientific Co. Ltd. Class H’s earnings last quarter?
Jenscare Scientific Co. Ltd. Class H released its earnings results on Mar 26, 2026. The company reported -HK$0.258 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.258.
Is Jenscare Scientific Co. Ltd. Class H overvalued?
According to Wall Street analysts Jenscare Scientific Co. Ltd. Class H’s price is currently Overvalued.
Does Jenscare Scientific Co. Ltd. Class H pay dividends?
Jenscare Scientific Co. Ltd. Class H does not currently pay dividends.
What is Jenscare Scientific Co. Ltd. Class H’s EPS estimate?
Jenscare Scientific Co. Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Jenscare Scientific Co. Ltd. Class H have?
Jenscare Scientific Co. Ltd. Class H has 310,306,200 shares outstanding.
What happened to Jenscare Scientific Co. Ltd. Class H’s price movement after its last earnings report?
Jenscare Scientific Co. Ltd. Class H reported an EPS of -HK$0.258 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 0.222%.
Which hedge fund is a major shareholder of Jenscare Scientific Co. Ltd. Class H?
Currently, no hedge funds are holding shares in HK:9877
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Jenscare Scientific Co. Ltd. Class H Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
201.35%
12-Months-Change
Fundamentals
Return on Equity
-22.25%
Trailing 12-Months
Asset Growth
-8.72%
Trailing 12-Months
Company Description
Jenscare Scientific Co. Ltd. Class H
Jenscare Scientific Co., Ltd., a medical device company, engages in the research and development of invasive interventional therapies for structural heart diseases in the People's Republic of China. The company offers LuX-Valve, a transcatheter tricuspid valve replacement (TTVR) product candidate for the treatment of severe tricuspid regurgitation and high surgical risk; and Ken-Valve, a transcatheter aortic valve replacement product candidate for the treatment of severe aortic regurgitation or combined with aortic stenosis. Its products have applications in the treatment of structural heart diseases, including tricuspid valve diseases, aortic valve diseases, mitral valve diseases, and heart failure. The company was incorporated in 2011 and is headquartered in Ningbo, the People's Republic of China.
Technical Analysis
Peijia Medical Ltd.
―
LifeTech Scientific Corporation
―
Shanghai Kindly Medical Instruments Co., Ltd. Class H
―
AK Medical Holdings Ltd.
―
MicroTech Medical (Hangzhou) Co., Ltd. Class H
―
Options Prices
Currently, No data available
---